Powered by

Soliton to Initiate POC Clinical Trials to Treat Fibrotic Scars Using Acoustic Shockwaves; Estimated Market Size of $10 Billion by 2025

Aug 29, 2019 - PR Newswire

PR Newswire

 Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it is planning a proof of concept (POC) clinical trial for the use of its RAP technology for the treatment of keloid and hypertrophic scars.

Keloid and hypertrophic scars represent wound healing gone awry.  A typical exa...